PUBLIC COMPANY
save$CGONCG Oncology, Inc.
$CGON77.61-3.81%Dallas, TX, USupdated 8h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- —An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
- phase2Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- phase2Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
- phase3Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
- phase3A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
- phase2Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 17, 26option exerciseMulay James · director15,600 sh
- Apr 17, 26option exerciseMulay James · director15,600 sh
- Apr 15, 26grantKasturi Vijay · Chief Medical Officer79,216 sh
- Apr 15, 26grantPatterson Joshua F. · See Remarks45,266 sh
- Apr 15, 26grantDETORE JAMES M. · Chief Financial Officer90,574 sh
- Apr 15, 26grantKuan Arthur · Chief Executive Officer271,600 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that